医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jiangsu Hengrui Medicine and Arcutis Announce a Development and Commercialization Partnership for Novel Immune-Mediated Dermatology Therapy Using SHR0302

2018年01月05日 PM10:00
このエントリーをはてなブックマークに追加


 

SHANGHAI & MENLO PARK, Calif.

Jiangsu Hengrui Medicine Co., Ltd. (SSE: 600276), a fully integrated biopharmaceutical company based in Shanghai, and Arcutis, Inc., a biotechnology company based in Menlo Park, CA, today announced an exclusive option and license agreement for the development and commercialization of topical applications of Hengrui’s investigational drug, SHR0302, for the treatment of dermatology disorders. SHR0302, a highly potent, selective JAK inhibitor, is currently being evaluated in Phase 2 clinical trials for rheumatoid arthritis in China.

“Arcutis has been formed around a team of industry veteran leaders with deep expertise and an admirable track record in developing and commercializing dermatology therapeutics,” said Lianshan Zhang, Ph.D., President of Global R&D of Hengrui. “There is high unmet need for a topical therapy with new mechanism of action to effectively address immune-mediated dermatology disorders. We are very excited to be a partner of Arcutis.”

“We are delighted to be partnering with Hengrui to develop topical applications of SHR0302,” said Howard Welgus, MD, Chief Medical Officer of Arcutis. “JAK inhibition is one of the most promising areas of innovation in topical treatments for immune-mediated dermatological disorders, and through its unique combination of potency and specificity, SHR0302 has the potential to be the ‘best-in-class’ topical JAK inhibitor.”

JAK-STAT signaling, which plays a critical role in immune and hematopoietic function, is an intracellular pathway upon which numerous different proinflammatory signals converge. SHR0302 is a novel JAK inhibitor designed to offer a greater therapeutic window through high selectivity, high potency, and an extended tissue half-life. Hengrui has completed a Phase 1 study in healthy volunteers in China and is currently pursuing clinical development of SHR0302 as a systemic therapy for a range of autoimmune disorders. There is growing evidence suggesting that inhibition of JAK may be broadly useful in dermatology.

“As one of the leading, research-driven biopharmaceutical companies in China, Hengrui is passionate about and committed to developing breakthrough medicines for patients,” said Piaoyang Sun, Ph.D., Chairman of Hengrui. “This collaboration is another step towards globalizing our mission. We look forward to bringing together capabilities of both companies and quickly developing SHR0302 for patients who need innovative, meaningful therapies.”

About Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $1.6 billion in 2016. Hengrui is devoted to empowering healthier lives through research, and currently has 3 programs under China NDA as well as 21 new molecular entities in clinical development in China, U.S., and Australia, across oncology, anesthesiology & pain management, immunology & inflammation, and cardiovascular & metabolic diseases.

About Arcutis, Inc.

Arcutis, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California that focuses on harnessing the power of biotechnology to develop and commercialize novel medical dermatology treatments. The company’s strategy is to develop a diversified pipeline of novel therapies that address areas of high unmet medical need in the treatment of medical dermatology diseases and disorders. Arcutis is led by a management team with extensive experience in product development and commercialization from many of the leading dermatology and biotechnology companies.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180105005143/en/

CONTACT

For Hengrui Medicine:
Paul Lu, Ph.D., +1-609-423-2155
Global
Business Development
or
Investor Relations:
ICR
Eric
Laub, +1-617-956-6733
Senior Vice President
Eric.Laub@icrinc.com
or
Media:
ICR
James
Heins, +1-203-682-8251
Senior Vice President
James.Heins@icrinc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品工業によるシャイアーの買収案を日本の公正取引委員会が承認
  • 武田拟收购Shire plc获得日本公平交易委员会批准
  • James Till教授因干细胞发现而荣获2018年度江户川Niche奖
  • Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
  • Brightree发布面向居家医疗器械的首个患者App